Bevacizumab

Bevacizumab Reactions 1680, p69 - 2 Dec 2017 Endophthalmitis following an off label use: case report In a retrospective study, one patient was described [age and sex not stated], who developed endophthalmitis following an off-label treatment with bevacizumab [Avastin]. The patient was started on intravitreal bevacizumab injection PRN as an off‑label therapy for an unspecified ocular condition [dose not stated]. However, following bevacizumab administration, the patient developed endophthalmitis, which was considered to be related with bevacizumab [duration of treatment to reaction onset and outcome not stated]. Subsequently, the patient underwent vitrectomy. Author comment: "Ocular adverse drug reactions (ADRs) noted in the study group that were given injections included three patients who developed endophthalmitis". "Of the three patients with endophthalmitis, two responded to intravitreal antibiotics alone whereas one underwent vitrectomy." "The purpose of this study was to evaluate the safety profile of intravitreal bevacizumab (Avastin) as an off-label pharmacotherapeutic agent for various ocular conditions." Jain P, et al. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian Journal of Ophthalmology 65: 596-602, No. 7, Jul 2017. Available from: URL: http://doi.org/10.4103/ijo.IJO_992_16 - India 803285034 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Bevacizumab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/bevacizumab-VZvD4UVepX
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39000-y
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p69 - 2 Dec 2017 Endophthalmitis following an off label use: case report In a retrospective study, one patient was described [age and sex not stated], who developed endophthalmitis following an off-label treatment with bevacizumab [Avastin]. The patient was started on intravitreal bevacizumab injection PRN as an off‑label therapy for an unspecified ocular condition [dose not stated]. However, following bevacizumab administration, the patient developed endophthalmitis, which was considered to be related with bevacizumab [duration of treatment to reaction onset and outcome not stated]. Subsequently, the patient underwent vitrectomy. Author comment: "Ocular adverse drug reactions (ADRs) noted in the study group that were given injections included three patients who developed endophthalmitis". "Of the three patients with endophthalmitis, two responded to intravitreal antibiotics alone whereas one underwent vitrectomy." "The purpose of this study was to evaluate the safety profile of intravitreal bevacizumab (Avastin) as an off-label pharmacotherapeutic agent for various ocular conditions." Jain P, et al. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian Journal of Ophthalmology 65: 596-602, No. 7, Jul 2017. Available from: URL: http://doi.org/10.4103/ijo.IJO_992_16 - India 803285034 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off